Metastatic melanoma patients (n = 10) who progressed on anti-PD-1 therapy received FMT from two donors who had previously been treated with nivolumab for metastatic melanoma and achieved complete response for at least one year. This evidence concerns the gene PDCD1 and metastatic melanoma.